KYS2301 gel approved for clinical use in atopic dermatitis
July 14, 2025
Source: drugdu
58
Kangyuan Pharmaceutical announced that the company recently received the "Drug Clinical Trial Approval Notice" for the Class 1 chemical new drug KYS2301 gel (three specifications) issued by the National Medical Products Administration. KYS2301 gel is the world's first peptide inhibitor targeting the CCR8 target, and its indication is atopic dermatitis. Preclinical studies have shown that KYS2301 has a high affinity for the CCR8 target, and topical application of KYS2301 gel has a good pharmacodynamic effect on the treatment of atopic dermatitis. Toxicology and pharmacokinetic studies have shown that KYS2301 gel is highly safe.
At present, the treatment drugs for atopic dermatitis mainly include topical corticosteroids, which have many adverse reactions and are not suitable for long-term use. The development of localized atopic dermatitis treatment drugs with better safety has important clinical significance.
https://www.nbd.com.cn/articles/2025-07-03/3932088.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Newly discovered drug class could someday lead to breakthrough treatments for fungal infections August 12, 2025
- FDA Approves Ajovy for Migraine Prevention in Children and Teens August 12, 2025
- The results of Phase 1 clinical trials indicate that cancer vaccines can prolong the recurrence free survival of patients August 12, 2025
- Bloomage Biotech’s fermentation-based chondroitin sodium completes medical device master file registration August 12, 2025
- Zhonghong Medical’s subsidiary, Kelun Medical Devices, plans to be selected for multiple medical consumables procurement projects August 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
